FINWIRES · TerminalLIVE
FINWIRES

Morgan Stanley Downgrades MapLight Therapeutics to Equalweight From Overweight, $34 PT

By

MapLight Therapeutics (MPLT) has an average rating of Buy and mean price target of $32.31, according to analysts polled by FactSet.

What else is happening in Research?